Pfizer Studies Israel's Coronavirus Vaccination Campaign
2021-02-13
LRC
TXT
大字
小字
滚动
全页
1Israel's fast vaccination effort is providing important information about drug company Pfizer's COVID-19 vaccine.
2Reporters with the Reuters news agency spoke to leading scientists in Israel and other places, Israeli health officials, hospital heads and two of the country's largest healthcare providers.
3The aim was to find the latest information about the country's especially fast vaccination campaign.
4About 3.5 million Israelis have been fully or partly vaccinated.
5That is more than half of people who are in groups that are supposed to be vaccinated first.
6These groups are showing a sharp drop in infections.
7Eran Segal is a data scientist at the Weizmann Institute of Science in Rehovot, Israel.
8He said there was a 53 percent reduction in new cases in the first fully vaccinated group.
9In addition, there were 39 percent fewer hospitalizations and a 31 percent drop in severe illnesses from the middle of January until February 6, Segal said.
10More information will be known in two weeks, as teams study the vaccine's effectiveness in younger groups of Israelis and people with certain conditions.
11"We need to have enough variety of people in that subgroup and enough follow-up time so you can make the right conclusions, and we are getting to that point," said Ran Balicer.
12He is an official with the Israeli health services provider Clalit.
13Pfizer is watching the Israeli effort each week to understand more about the vaccine and how it is working.
14Israel's campaign provides Pfizer and its partner, Germany's BioNTech, with an unusual chance.
15The small country has healthcare for all its citizens, and the ability to gather and study data.
16Israel also has quickly provided the vaccine to its citizens.
17Israel still faces struggles in its effort to fight the virus.
18The country's third national lockdown has not slowed the spread of COVID-19.
19A fast-spreading variant of the virus that was first found in Britain is now spreading in Israel.
20So far, the Pfizer/BioNTech shot appears to be effective against it.
21"We've so far identified the same 90 percent to 95 percent efficacy against the British strain," said Hezi Levi.
22He is a director-general of the Israeli Health Ministry.
23The Pfizer vaccine requires two doses, or shots, to be effective.
24For this reason, Levi said it is too early to know about levels of protection because many people only received the second dose in the last week.
25He added that it is still too early to know whether the vaccine is effective against another fast-spreading virus variant that began in South Africa.
26Israel began its vaccination program on December 19.
27It paid a high price for supplies of the Pfizer/BioNTech vaccine.
28Four days later, the fast-spreading British variant was found in four people in Israel.
29After that, Israel decided to begin giving shots to people over the age of 60.
30Over time, it has opened the program to the rest of the population.
31Information gathered by Israeli healthcare provider Maccabi shows that only six out of every 10,000 people got infected with COVID-19 one week after receiving their second Pfizer dose.
32By 22 days after full vaccination, no infections were recorded.
33Pfizer says its vaccine's effectiveness starts one week after the second dose is given.
34One important question is whether vaccines can end the pandemic.
35Michal Linial is a professor of molecular biology and bioinformatics at Jerusalem's Hebrew University.
36She said data from the past suggests that viruses become endemic and seasonal.
37She predicted the coronavirus would become far less aggressive, possibly requiring an additional shot within three years.
38She added, "The virus is not going anywhere."
39I'm Mario Ritter Jr.
1Israel's fast vaccination effort is providing important information about drug company Pfizer's COVID-19 vaccine. 2Reporters with the Reuters news agency spoke to leading scientists in Israel and other places, Israeli health officials, hospital heads and two of the country's largest healthcare providers. The aim was to find the latest information about the country's especially fast vaccination campaign. 3About 3.5 million Israelis have been fully or partly vaccinated. That is more than half of people who are in groups that are supposed to be vaccinated first. These groups are showing a sharp drop in infections. 4Eran Segal is a data scientist at the Weizmann Institute of Science in Rehovot, Israel. He said there was a 53 percent reduction in new cases in the first fully vaccinated group. In addition, there were 39 percent fewer hospitalizations and a 31 percent drop in severe illnesses from the middle of January until February 6, Segal said. 5More information will be known in two weeks, as teams study the vaccine's effectiveness in younger groups of Israelis and people with certain conditions. 6"We need to have enough variety of people in that subgroup and enough follow-up time so you can make the right conclusions, and we are getting to that point," said Ran Balicer. He is an official with the Israeli health services provider Clalit. 7Pfizer is watching the Israeli effort each week to understand more about the vaccine and how it is working. 8Israel's campaign provides Pfizer and its partner, Germany's BioNTech, with an unusual chance. The small country has healthcare for all its citizens, and the ability to gather and study data. Israel also has quickly provided the vaccine to its citizens. 9Israel still faces struggles in its effort to fight the virus. The country's third national lockdown has not slowed the spread of COVID-19. A fast-spreading variant of the virus that was first found in Britain is now spreading in Israel. So far, the Pfizer/BioNTech shot appears to be effective against it. 10"We've so far identified the same 90 percent to 95 percent efficacy against the British strain," said Hezi Levi. He is a director-general of the Israeli Health Ministry. 11The Pfizer vaccine requires two doses, or shots, to be effective. For this reason, Levi said it is too early to know about levels of protection because many people only received the second dose in the last week. He added that it is still too early to know whether the vaccine is effective against another fast-spreading virus variant that began in South Africa. 12Good results so far 13Israel began its vaccination program on December 19. It paid a high price for supplies of the Pfizer/BioNTech vaccine. 14Four days later, the fast-spreading British variant was found in four people in Israel. 15After that, Israel decided to begin giving shots to people over the age of 60. Over time, it has opened the program to the rest of the population. 16Information gathered by Israeli healthcare provider Maccabi shows that only six out of every 10,000 people got infected with COVID-19 one week after receiving their second Pfizer dose. By 22 days after full vaccination, no infections were recorded. 17Pfizer says its vaccine's effectiveness starts one week after the second dose is given. 18One important question is whether vaccines can end the pandemic. Michal Linial is a professor of molecular biology and bioinformatics at Jerusalem's Hebrew University. She said data from the past suggests that viruses become endemic and seasonal. 19She predicted the coronavirus would become far less aggressive, possibly requiring an additional shot within three years. 20She added, "The virus is not going anywhere." 21I'm Mario Ritter Jr. 22Maayan Lubell and Ari Rabinovitch reported this story for Reuters. Mario Ritter Jr. adapted it for VOA Learning English. Ashley Thompson was the editor. 23________________________________________________________________ 24Words in This Story 25variety -n. a number or collection of different things or people 26conclusion -n. a final opinion or judgement 27strain -n. a group of closely related living things 28dose -n. the amount of medicine or vaccine needed to cure or help a condition 29contagious -adj. able to be passed from one person or animal to another 30endemic -n. common to a place 31We want to hear from you. Write to us in the Comments section, and visit our Facebook page.